GLP-1 agonists are among the most consequential and impactful drug classes in recent history. Used to treat type 2 diabetes, obstructive sleep apnea, obesity, and cardiovascular disease, injectable GLP-1s are hailed for their efficacy (15% to 21% of body weight lost in 18 months of use, on average) and for their wide-reaching benefits. Recent research suggests they may benefit patients with liver disease, alcohol use disorder, some cancers, and more.

In 2026, the availability and affordability of tirzepatide and semaglutide — the most popular GLP-1s on the market — are poised to explode. Pill formulations are on the horizon, and a recent deal between drug makers and the U.S. government promises expanded Medicare and Medicaid coverage of these medications, as well as discounted prescriptions of $150 to $350 per month.

As the treatment landscape shifts beneath our feet, this timely webinar will help attendees do the following:

• Explore the full range of obesity treatments on the market today
• Understand the mechanisms, benefits, and side effects associated with GLP-1 agonists
• Recognize all indications and appropriate patients for GLP-1 agonists
• Study the complementary lifestyle strategies needed to protect lean muscle mass and ensure adequate intake of vitamins and minerals while taking GLP-1s
• Understand the history of these medications and how the market is shifting in 2026 and beyond